If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.522
Bid: 1.50
Ask: 1.58
Change: 0.015 (0.98%)
Spread: 0.08 (5.333%)
Open: 1.50
High: 1.536
Low: 1.47
Prev. Close: 1.525
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

Thu, 28th Sep 2023 14:24

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Dar Global PLC - luxury international real estate developer - In the six months that ended June 30, pretax profit multiplies to GBP20.8 million from GBP3.7 million a year earlier. Revenue also multiplies to GBP108.4 million from GBP27.5 million. Chief Executive Officer Ziad El Chaar says: "2023 has been a milestone year for the company with our successful listing on the London Stock Exchange in February representing a significant step forward in supporting our ambitious growth trajectory. The second half has started strongly and we are well positioned to weather some of the challenges facing the sector through the strength of our balance sheet, building partnerships with other global luxury brands and further expanding our pipeline of opportunities."

----------

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - In the six months that ended June 30, pretax loss widens to GBP4.3 million from GBP1.1 million. Posts no revenue, unchanged, while administrative expenses widen to GBP3.9 million from GBP1.1 million. Chief Executive Officer Vladislav Sandler says: "While the placing of Hemo-Car-T on clinical hold was a setback, we are clear on the particular area in which additional information is required, and we are encouraged by the [US Food & Drug Administration]'s response to our plans to resolve the issues. We remain confident and committed to progressing Hemo-Car-T to clinical trials as the company's next step. We have put measures in place to allow us to achieve this milestone, including the new agreement with Prevail InfoWorks and the investment by Prevail Partners, which gives a clear signal of the project's value even at this pre-clinical phase. Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."

----------

Lansdowne Oil & Gas PLC - North Celtic Sea-focused oil and gas company - In the six months that ended June 30, pretax loss widens to GBP16.1 million from GBP158,000 a year earlier. This is due to a one-off impairment of intangible assets of GBP15.9 million. Says it remains confident of amicable resolution with Ireland over Barryroe oil field, after receiving a letter in May from the Irish Department of the Environment, Climate & Communications, advising that the minister would not grant the lease undertaking, as sought, on grounds of financial capability. Says: "We continue to maintain that the failure to allow the Barryroe oil and gas field to progress to development is against the best interests of Ireland."

----------

Metals One PLC - London-based mining company, which is focused on battery metals projects in Finland and Norway - In the six months that ended June 30, pretax loss narrows to GBP118,893 from GBP154,371 a year earlier, as administrative expenses narrow to GBP118,893 from GBP184,017. Chair Alastair Clayton says: "The six-month period...was incredibly busy for the company as it worked towards completion of its [initial public offering] and concurrent acquisitions of European brownfield battery metals projects which occurred after the reporting period. With European brownfield projects, experienced partners, and funded work programmes in place, our projects are well positioned for rapid advancement as we seek to establish ethically mined sources of critical minerals, including nickel, in Europe, close to future customers. Exploration in Norway is well underway with Kingsrose, whilst in Finland we are finalising plans to commence phase one drilling in the near future. We look forward to updating shareholders on further news as we continue our work programmes."

----------

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - In the six months that ended June 30, pretax loss narrows to GBP1.6 million from GBP1.7 million a year earlier. Total income during the period was up to GBP1.2 million from GBP656,000 a year earlier, with revenue up to GBP770,000 from GBP391,000. Chief Executive Officer Ilian Iliev says: "During the first half of 2023 we have made significant progress and achieved important milestones as we continue to successfully execute on our 'evergreen' strategy, covering core operating costs through a combination of corporate finance fees and value creation services fees via our wholly owned subsidiary, EMV Capital. We have also demonstrated our ability to generate profitable partial exits from our portfolio, even in the absence of a strong [mergers & acquisitions] or [initial public offering] market. This essential funding for our portfolio companies has helped to facilitate the execution of their growth strategies and preparations for forthcoming scale-up investment rounds as well as supporting the appreciating fair value of NetScientific's direct holdings. In such a challenging venture capital landscape, characterised by macroeconomic volatility and industry fluctuations, our in-house fundraising capacity distinguishes us from many of our peers."

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
13 Jul 2020 18:25

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

Read more
30 Jun 2020 17:07

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

UK DIRECTOR DEALINGS SUMMARY: TalkTalk Telecom Chair Pays GBP860,000

Read more
26 Jun 2020 14:50

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

IN BRIEF: Hemogenyx Inks Investigation And Material Supply Deal

Read more
15 Jun 2020 17:54

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
12 May 2020 18:09

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Hemogenyx Pharma Placing Raises GBP2.5 Million To Fund Studies

Read more
1 May 2020 11:18

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

UK EARNINGS SUMMARY: InfraStrata Targets Breakeven At Titanic Shipyard

Read more
22 Apr 2020 15:40

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

UK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order

Read more
22 Apr 2020 06:55

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Hemogenyx Approved For And Issued Hu-PHEC Patent In Europe

Read more
20 Feb 2020 15:15

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Hemogenyx Reports Positive Test Results From Cancer Therapy Treatment

Read more
11 Feb 2020 12:00

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Hemogenyx Gets US Patent For Postnatal Hemogenic Endothelial Cells

Read more
30 Jan 2020 15:47

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Hemogenyx Raises GBP648,200 To Continue T Cell Therapy Development

Read more
15 Jan 2020 13:23

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Hemogenyx Shares Jump On Promising Data From Blood Cancer Therapy

Read more
18 Nov 2019 11:51

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Hemogenyx CDX Antibody Treatment Potentially "Life-Saving"

Read more
23 Oct 2019 10:43

Hemogenyx signs another deal with unnamed global pharma company

(Sharecast News) - Biopharmaceutical group Hemogenyx Pharmaceuticals announced on Wednesday that its wholly-owned subsidiary Immugenyx has entered into a research agreement with a global pharmaceutical company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.